Christoph B. Olivier: CYP2C19 Genotype, Platelet Reactivity and Risk Stratification in AF Patients Undergoing PCI
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn about a recent article he and his colleagues co-authored, published in ASCPT:
”We are excited to share our latest publication: CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Patients with atrial fibrillation undergoing PCI are among the highest-risk groups in interventional cardiology, facing competing ischemic and bleeding risks under complex antithrombotic therapy.
We assessed whether CYP2C19 genotype and platelet reactivity testing improve risk stratification in this vulnerable population.
Key findings:
- Poor/intermediate CYP2C19 metabolizer status might indicate lower bleeding risk
- High platelet reactivity identified patients at increased ischemic risk
- Low platelet reactivity was strongly associated with major bleeding
While larger studies are needed, such approaches may help improve risk stratification and guide individualized antithrombotic therapy.
A huge thank you to all the authors and colleagues for their incredible work on this project: Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, Dr. David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann.”
Title: CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Authors: Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B. Olivier

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series